Floatz logo

pf-01913539

Dementia

PfizerPhase 2Dormant
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
81/ 100

Competitive context

44 Active assets in the Dementia cohort.

Asset / SponsorPhaseRating
Risperdal
Hannover Medical School
Phase 4BBB
CITALOPRAM
Hannover Medical School
Phase 4BBB
Galantamine Hydrobromide
Janssen Pharmaceutica N.V., Belgium
Phase 3BB
Namenda
Zealand University Hospital
Phase 4BB
Cipralex
Ohio State University
Phase 4BB

View all 50 →

Same molecule, other indications

pf-01913539 is also rated in:

Alzheimer diseaseDormant
CCC
Indicative ·
51 / 100
View asset →
DimebonDormant
NR
Indicative ·
/ 100
View asset →
Investigational DrugDormant
NR
Indicative ·
/ 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →